Clinical trials: multiple sclerosis
Relapsing-remitting Multiple Sclerosis
Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis
The purpose of this study was to determine the dose-response curve for the MRI-based efficacy of BAF312 compared with placebo in patients with Relapsing-Remitting Multiple Sclerosis (RRMS), and to characterize its safety and…
- Trial name
- NCT00879658
- Testing
- BAF312
- Where
- 72 sites in United States, Canada and 10 more
- Volunteers
- 297 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis
This study evaluated the safety, tolerability and effect on MRI lesion parameters of FTY720 in patients with relapsing multiple sclerosis.
- Trial name
- NCT00333138
- Testing
- FTY720
- Where
- 26 sites in Canada, Denmark and 9 more
- Volunteers
- 281 people
- Sponsor
- Novartis
Multiple Sclerosis
The Multicenter, Open-label, Single-use Autoinjector Convenience Study
The purpose of this trial is to test the Single-Use Autoinjector for a) ease of use; b) multiple domains related to subject's acceptability and satisfaction, and c) reliability of the correct function for self-injection of Rebif®…
- Trial name
- NCT00958009
- Testing
- Rebidose®
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- EMD Serono
Multiple Sclerosis
The Therapeutic Effects of Forced Aerobic Exercise in Multiple Sclerosis
This project will investigate the feasibility and initial efficacy of two aerobic exercise training approaches, forced and voluntary, to improve motor function in persons with multiple sclerosis (MS).
- Trial name
- NCT04906057
- Testing
- Forced Aerobic Exercise (FE), Voluntary Aerobic Exercise (VE)
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- The Cleveland Clinic
Multiple Sclerosis
Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
This study assessed the safety, tolerability and efficacy of two doses of oral fingolimod compared to placebo on efficacy parameters in patients with relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- FREEDOMS II (NCT00355134)
- Testing
- Fingolimod
- Where
- 112 sites in United States, Australia and 6 more
- Volunteers
- 1,083 people
- Sponsor
- Novartis
Relapsing-Remitting Multiple Sclerosis
Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis
To determine if treatment with BG00012 can decrease the number of MS relapses during a certain time period. To determine if, over time, BG00012 treatment can decrease the number of certain types of brain lesions commonly seen in…
- Trial name
- DEFINE (NCT00420212)
- Testing
- BG00012
- Where
- 159 sites in United States, Australia and 27 more
- Volunteers
- 1,234 people
- Sponsor
- Biogen
Multiple Sclerosis
Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients
The trial consists of a dose escalation, to establish the safety of ofatumumab in RRMS patients. A 48-week treatment period followed by an individualized follow-up period until normalization of peripheral B-cell counts or…
- Trial name
- OMS115102 (NCT00640328)
- Testing
- Ofatumumab 100, Ofatumumab 300, Ofatumumab 700
- Volunteers
- 38 people
- Sponsor
- GlaxoSmithKline
Multiple Sclerosis
Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a
This is a prospective, monocentric, double blind, placebo controlled, two arm study. Curcumin is derived from the rhizomes of the plant Curcuma longa (common name, turmeric) belonging to the Zingiberaceae family found in South…
- Trial name
- CONTAIN (NCT01514370)
- Testing
- IFN beta 1a 44 mcg TIW, Curcumin
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis, Primary Progressive
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
This study will evaluate the efficacy and safety of ocrelizumab (Ocrevus®) compared with placebo in participants with primary progressive multiple sclerosis (PPMS), including participants later in their disease course.
- Trial name
- O'HAND (NCT04035005)
- Testing
- Ocrelizumab
- Where
- 155 sites in United States, Australia and 21 more
- Volunteers
- 1,013 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis
Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)
This clinical study compares the efficacy, safety, and tolerability of therapy with ponesimod vs placebo in subjects with active RMS who are treated with DMF (Tecfidera®).
- Trial name
- POINT (NCT02907177)
- Testing
- Ponesimod
- Where
- 119 sites in United States, Australia and 18 more
- Volunteers
- 136 people
- Sponsor
- Actelion
Relapsing Multiple Sclerosis (RMS)
Effects of Cladribine Tablets on the PK of Microgynon®
The purpose of this study was to investigate the potential effects of cladribine on the pharmacokinetics (PK) of monophasic oral contraceptive microgynon® by assessment of its constituents, ethinyl estradiol (EE) and…
- Trial name
- NCT03745144
- Testing
- Cladribine, Microgynon®
- Where
- 7 sites in Germany, Poland
- Volunteers
- 28 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Tuberous Sclerosis Complex, Seizures
An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)
This trial consists of 2 parts: a double-blinded phase and an open-label extension phase. The open-label extension phase only will be described in this record. All participants will receive the same dose of GWP42003-P.
- Trial name
- NCT02544750
- Testing
- GWP42003-P
- Where
- United States
- Volunteers
- 199 people
- Sponsor
- Jazz Pharmaceuticals
Multiple Sclerosis, Lower Urinary Tract Symptoms
Central Nervous System Changes Following OnabotulinumtoxinA Injection in the Bladder
The purpose of this research study is to evaluate higher neural changes following intra-detrusor injection of Onabotulinumtoxin-A (BTX-A) in patients with Multiple Sclerosis (MS).
- Conditions
- Multiple Sclerosis, Lower Urinary Tract Symptoms, Neurogenic Bladder, Detrusor, Overactive
- Trial name
- NCT03033355
- Testing
- Intra-detrusor injection of Onabotulinumtoxin-A
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- The Methodist Hospital Research Institute
Amyotrophic Lateral Sclerosis (ALS)
Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)
ALS is a disorder that weakens motor strength and lung function. Rapid loss of motor neurons in the brain and spinal cord of ALS patients causes the symptoms of increasing weakness and loss of muscle function.
- Trial name
- NCT01232738
- Testing
- rasagiline
- Where
- 10 sites in United States, Canada
- Volunteers
- 36 people
- Sponsor
- Yunxia Wang, MD
Multiple Sclerosis, Neurogenic Bladder
Vaginal Estriol in Multiple Sclerosis
Study to evaluate the efficiency of vaginal estriol, as a treatment for urogenital symptoms in female patients with RRMS. The secondary objective is to evaluate the potential role of vaginal estriol in re-myelination in RRMS…
- Trial name
- NCT03774407
- Testing
- vaginal estriol
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Texas Tech University Health Sciences Center
Relapsing-Remitting Multiple Sclerosis
Safety and Tolerability of Glatiramer Acetate
This is an open-label, randomized, multi-center, parallel-arm study to assess the safety and tolerability of a daily dose of Glatiramer Acetate (GA) 40 mg/mL three times a week (TIW) administered subcutaneously (SC) as compared…
- Trial name
- GLACIER (NCT01874145)
- Testing
- GA 20 mg/mL, GA 40 mg/mL
- Where
- 35 sites in United States
- Volunteers
- 209 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Multiple Sclerosis, Relapsing-Remitting
ACTH for Fatigue in Multiple Sclerosis Patients
This is a study of Acthar gel (ACTH) in patients with relapsing multiple sclerosis who are experiencing chronic fatigue.
- Trial name
- ACTH (NCT02315872)
- Testing
- ACTH
- Where
- 5 sites in United States
- Volunteers
- 8 people
- Sponsor
- Providence Health & Services
Multiple Sclerosis
Validity and Reliability of the 6-minute Walk Test Over a Distance of 6 Metres in People With Multiple Sclerosis
The objective of this study is to validate a different version of the 6 minutes Walk Test (6minWT), the 6minWT on 6 meters, instead of the 30 meters.
- Trial name
- VR6minWT6 (NCT04228328)
- Testing
- The 6-minutes Walk Test
- Where
- Switzerland
- Volunteers
- 21 people
- Sponsor
- Haute Ecole de Santé Vaud
Spasticity, Cerebrovascular Accident
Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity
Phase 2/3, randomized, double-blind, placebo-controlled, single-treatment, multicenter trial assessing the efficacy and safety of MYOBLOC for the treatment of upper limb spasticity in adults followed by an open-label extension…
- Conditions
- Spasticity, Cerebrovascular Accident, Multiple Sclerosis, Traumatic Brain Injury
- Trial name
- NCT04815967
- Testing
- Phase 2; Low Dose MYOBLOC (10,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 3; MYOBLOC
- Where
- 9 sites in United States, Hungary and 1 more
- Volunteers
- 32 people
- Sponsor
- Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC
Multiple Sclerosis
Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis
This study evaluates the use of single agent ublituximab, a novel monoclonal antibody, in participants with relapsing forms of multiple sclerosis.
- Trial name
- NCT02738775
- Testing
- Ublituximab
- Where
- 12 sites in United States
- Volunteers
- 49 people
- Sponsor
- TG Therapeutics, Inc.